S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.10
+62.50
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
TECX · Tectonic Therapeutic, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Tectonic Therapeutic Inc (TECX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$21.86
+0.22
(+1.04%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$21.86
$21.58
$22.15
52-WEEK RANGE
$21.86
$15.52
$39.53
What's happening
- TECX is up 1.04% today, trading at $21.86. — Live quote
- Volume today (9,242) is well below its 3-month average of 209,680. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.18 actual vs. $-1.38 estimated (+14.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TECX
+4.63%
vs S&P 500
-8.15%
1-YEAR RETURN
TECX
+14.57%
vs S&P 500
+0.01%
6-MONTH RETURN
TECX
-26.47%
3-MONTH RETURN
TECX
-33.46%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.18
Est. $-1.38
BEAT +14.6%
2026-04-26 (Q1 2026)
$-1.34
Est. $-1.21
MISS -11.1%
2026-01-26 (Q4 2025)
$-1.03
Est. $-1.13
BEAT +8.5%
2025-10-26 (Q3 2025)
$-1.02
Est. $-1.07
BEAT +4.5%
Valuation Measures & Ratios
Enterprise Value4$194.8M
Forward P/E5—
PEG Ratio6-0.37
Price / Sales (TTM1)—
Price / Book72.90
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-35.26%
Return on Assets (ROA9)-33.59%
Avg Volume (3M)209,680
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $644.1M | $583.9M | $292.1M | $123.5M | $10.1M |
| P/E | -7.44 | -7.28 | -4.02 | -1.86 | -0.16 |
| Price/Book | 2.88 | 2.53 | 1.09 | 0.44 | 0.03 |
| EV/EBITDA | -4.41 | -3.92 | -0.29 | — | — |
| ROE | -38.66% | -34.79% | -27.15% | -23.36% | -20.43% |
| ROA | -36.51% | -32.51% | -26.22% | -22.44% | -19.54% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,222,184
Change from Prior Settlement+0.16%
% of Float—
Days to Cover (Short Ratio)8.07
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +14.6%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TECX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$24.2M | -$27.3M | -$21.9M | -$22.3M | -$18.3M | -$19.6M | -$11.4M | -$13.0M |
| Net income | -$22.3M | -$25.2M | -$19.0M | -$20.0M | -$15.9M | -$17.7M | -$12.7M | -$15.2M |
| EPS (diluted) | $-1.18 | $-1.34 | $-1.02 | $-1.07 | $-0.93 | $-1.20 | $-4.34 | $-10.97 |
| EPS (basic) | $-1.18 | $-1.34 | $-1.02 | $-1.07 | $-0.93 | $-1.20 | $-4.34 | $-10.97 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $237.0M | $246.6M | $261.0M | $277.0M | $295.3M | $314.8M | $152.9M | $168.7M |
| Total liabilities | $13.2M | $16.2M | $9.7M | $9.5M | $11.5M | $13.8M | $12.1M | $18.4M |
| Stockholders' equity | $223.8M | $230.4M | $251.3M | $267.5M | $283.8M | $301.0M | $140.8M | $150.4M |
| Total current assets | $231.1M | $239.9M | $257.4M | $273.2M | $290.8M | $309.6M | $146.9M | $162.6M |
| Total current liabilities | $10.4M | $13.0M | $9.7M | $9.4M | $11.4M | $13.5M | $11.6M | $17.3M |
| Cash & equivalents | $227.1M | $236.9M | $253.8M | $268.4M | $287.4M | $306.2M | $141.2M | $159.1M |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $858.0K | $1.0M | $1.2M | $1.4M | $1.7M | $1.9M | $2.2M | $2.5M |
| Other non-current assets | $626.0K | $663.0K | $640.0K | $597.0K | $287.0K | $138.0K | $156.0K | $190.0K |
| Accounts payable | $1.7M | $2.6M | $1.1M | $1.5M | $2.8M | $6.3M | $976.0K | $2.6M |
| Accrued liabilities | $7.1M | $9.0M | $7.3M | $6.8M | $6.8M | $4.9M | $7.8M | $12.7M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K |
| Retained earnings | -$270.3M | -$248.0M | -$222.7M | -$203.5M | -$184.5M | -$164.5M | -$148.6M | -$136.2M |
| Accumulated other comprehensive income (loss) | $0 | $0 | -$96.0K | -$75.0K | -$49.0K | $2.0K | $9.0K | -$77.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.5M | -$18.4M | -$14.5M | -$17.8M | -$14.7M | -$13.1M | -$16.8M | -$19.6M |
| Investing cash flow | -$59.0K | -$19.0K | $0 | -$166.0K | $55.0K | -$27.0K | -$3.0K | -$153.0K |
| Financing cash flow | $11.7M | $847.0K | -$141.0K | -$457.0K | -$4.2M | $178.1M | -$1.1M | -$6.3M |
| Free cash flow | -$21.5M | -$18.4M | -$14.5M | -$18.0M | -$14.7M | -$13.1M | -$16.8M | -$19.8M |
| Capital expenditures | $79.0K | $19.0K | $0 | $181.0K | $0 | $27.0K | $3.0K | $153.0K |
| Depreciation & amortization | $285.0K | $304.0K | $333.0K | $342.0K | $340.0K | $360.0K | $508.0K | $424.0K |
| Share-based compensation | $4.0M | $3.2M | $3.0M | $2.8M | $2.6M | $2.1M | $1.1M | $1.6M |
| Deferred income taxes | — | — | $18.7M | — | — | — | $16.9M | — |
| Change in accounts payable | -$799.0K | $1.4M | -$343.0K | -$1.3M | $137.0K | $1.6M | -$1.4M | $86.0K |
| Debt issued | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $77.0K | $412.0K | $0 | $0 | $17.0K | $0 | $0 | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$84.0M | -$58.0M | -$44.6M | -$105.4M | -$118.8M |
| Net income | -$74.2M | -$58.0M | -$42.8M | -$105.9M | -$119.1M |
| EPS (diluted) | $-4.05 | $-6.83 | $-33.76 | $-2.42 | $-2.78 |
| EPS (basic) | $-4.05 | $-6.83 | $-33.76 | $-2.42 | $-2.78 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $261.0M | $152.9M | $39.4M | $103.9M | $203.8M |
| Total liabilities | $9.7M | $12.1M | $43.4M | $28.6M | $34.4M |
| Stockholders' equity | $251.3M | $140.8M | -$84.6M | -$45.7M | $169.5M |
| Total current assets | $257.4M | $146.9M | $30.9M | $100.0M | $199.1M |
| Total current liabilities | $9.7M | $11.6M | $40.9M | $13.1M | $19.4M |
| Cash & equivalents | $253.8M | $141.2M | $28.8M | $92.6M | $189.6M |
| Other current assets | — | — | $570.0K | $1.0M | $1.7M |
| Property, plant & equipment | $1.2M | $2.2M | $3.1M | $2.9M | $4.1M |
| Other non-current assets | $640.0K | $156.0K | $31.0K | $40.0K | $74.0K |
| Accounts payable | $1.1M | $976.0K | $409.0K | $384.0K | $3.5M |
| Accrued liabilities | $7.3M | $7.8M | $8.1M | $11.7M | $15.6M |
| Long-term debt | — | — | — | $15.0M | $15.0M |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $2.0K | $2.0K | $0 | $4.0K | $4.0K |
| Retained earnings | -$222.7M | -$148.6M | -$90.6M | -$489.4M | -$383.5M |
| Accumulated other comprehensive income (loss) | -$96.0K | $9.0K | -$11.0K | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$60.1M | -$59.1M | -$40.7M | -$97.2M | -$98.0M |
| Investing cash flow | -$138.0K | -$156.0K | -$279.0K | -$267.0K | -$2.5M |
| Financing cash flow | $173.4M | $171.7M | $33.7M | $262.0K | $30.4M |
| Free cash flow | -$60.3M | -$59.2M | -$41.0M | -$97.5M | -$100.5M |
| Capital expenditures | $208.0K | $156.0K | $279.0K | $267.0K | $2.5M |
| Depreciation & amortization | $1.4M | $1.6M | $1.5M | $1.4M | $1.4M |
| Share-based compensation | $10.5M | $3.5M | $1.1M | $11.5M | $18.6M |
| Deferred income taxes | $18.7M | $16.9M | $14.6M | $0 | $0 |
| Change in accounts payable | $116.0K | -$1.4M | -$165.0K | -$3.1M | $804.0K |
| Debt issued | — | — | — | $0 | $15.0M |
| Tax withholding on stock comp | $17.0K | $0 | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TECX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-06 to 2026-09-30
Recent transactions
- Insiders have net sold 1,859 shares over the last 182 days, across 0 purchases and 5 sales.
- Most recent: McNamara Peter (Chief Scientific Officer) — Open market sale of 536 shares on 2026-09-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)1,859 sh(5 txns)
Net Shares-1,859
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| McNamara Peter | Chief Scientific Officer | Open market sale | 2026-09-30 | 536 |
| Lochner Daniel | Chief Financial Officer | Tax withholding | 2026-09-25 | 520 |
| Ruddy Marcella K. | Chief Medical Officer | Tax withholding | 2026-09-25 | 525 |
| REICIN ALISE | Chief Executive Officer | Tax withholding | 2026-09-25 | 1,545 |
| Schwabish Marc | Chief Business Officer | Tax withholding | 2026-09-25 | 411 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | McNamara Peter | Chief Scientific Officer | Open market sale | 536 | $23.04 |
| 2026-09-25 | Lochner Daniel | Chief Financial Officer | Tax withholding | 520 | $23.67 |
| 2026-09-25 | McNamara Peter | Chief Scientific Officer | Tax withholding | 444 | $23.67 |
| 2026-09-25 | Ruddy Marcella K. | Chief Medical Officer | Tax withholding | 525 | $23.67 |
| 2026-09-25 | REICIN ALISE | Chief Executive Officer | Tax withholding | 1,545 | $23.67 |
| 2026-09-25 | Schwabish Marc | Chief Business Officer | Tax withholding | 411 | $23.67 |
| 2026-08-25 | McNamara Peter | Chief Scientific Officer | Option exercise | 43 | $14.71 |
| 2026-08-25 | McNamara Peter | Chief Scientific Officer | Open market sale | 43 | $36.52 |
| 2026-08-12 | McNamara Peter | Chief Scientific Officer | Option exercise | 43 | $14.71 |
| 2026-08-12 | McNamara Peter | Chief Scientific Officer | Open market sale | 43 | $35.00 |
| 2026-06-30 | McNamara Peter | Chief Scientific Officer | Option exercise | 172 | $14.71 |
| 2026-06-30 | McNamara Peter | Chief Scientific Officer | Open market sale | 172 | $35.00 |
| 2026-06-20 | REICIN ALISE | Chief Executive Officer | Tax withholding | 924 | $30.34 |
| 2026-05-04 | Ruddy Marcella K. | Chief Medical Officer | Open market sale | 1,065 | $30.00 |
| 2026-04-01 | Ruddy Marcella K. | Chief Medical Officer | Open market sale | 1,000 | $31.05 |
| 2026-03-06 | Ruddy Marcella K. | Chief Medical Officer | Open market sale | 10,000 | $30.00 |
| 2026-03-06 | McNamara Peter | Chief Scientific Officer | Option exercise | 2,500 | $2.38 |
| 2026-03-06 | McNamara Peter | Chief Scientific Officer | Option exercise | 215 | $14.71 |
| 2026-03-06 | McNamara Peter | Chief Scientific Officer | Open market sale | 6,047 | $30.00 |
| 2026-03-06 | McNamara Peter | Chief Scientific Officer | Open market sale | 215 | $35.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:12 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 4 | 2026-09-25 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-25 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-25 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-25 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-09-25 | View on SEC.gov → |
| 2026-09-29 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-08-26 | 4 | 2026-08-25 | View on SEC.gov → |
Recent news
Headlines about TECX (Tectonic Therapeutic, Inc.). Links open the publisher — we don’t host full articles.
-
TECX Nov 2026 30.000 call (TECX261120C00030000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-19 -
(TECX) Equity Market Report (TECX:CA)
Stock Traders Daily · 2026-10-19 -
Understanding Momentum Shifts in (TECX)
Stock Traders Daily · 2026-10-16 -
Tectonic Therapeutic, Inc. (TECX) Presents at CureHHT 16thHHT International Scientific Conference - Slideshow
SeekingAlpha · 2026-10-14 -
UBS Initiates Coverage On Tectonic Therapeutic with Neutral Rating, Announces Price Target of $26
Benzinga · 2026-10-12 -
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
Yahoo Finance · 2026-09-29 -
Tectonic Therapeutic (TECX) Clears Two Trial Hurdles With Cash To Spare
Yahoo Finance · 2026-09-10 -
Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case
Seeking Alpha · 2026-09-02
No headlines in this category right now — try “All”.